Impact of ‘dry days’ on quality of life in patients with ‘wet’ overactive bladder: results of a pooled analysis of three phase III studies with darifenacin

Newman D1, Larson-Peters A2, Seifu Y3, Aronstein W4, Mongay L3

Abstract Category

Quality of Life (QoL)

Abstract 56
Quality of Life & Epidemiology
Scientific Podium Poster Session 6
Thursday 1st October 2009
15:15 - 15:20
Hall C
1. University of Pennsylvania, 2. Procter & Gamble Pharmaceuticals, 3. Novartis Pharmaceuticals Corporation, 4. CTI Clinical Trial & Consulting Services

D Newman